2018 / 03

Next Paper
DOI: 10.24075/brsmu.2018.032

ORIGINAL RESEARCH

Persistence of oncolytic Coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy

Sidorenko AS1, Zheltukhin AO1, Le TH1, Soboleva AV1,2, Lipatova AV1, Golbin DA3, Chumakov PM1,2
About authors

1 Engelhardt Institute of Molecular Biology, Moscow

2 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow

3 Burdenko National Medical Research Center of Neurosurgery, Moscow

Correspondence should be addressed: Peter M. Chumakov
Vavilova 32, Moscow, 119991; moc.oohay@mpvokamuhc

About paper

Funding: the study was supported by the Ministry of Education and Science of the Russian Federation; project code RFMEFI60714X0014.

Received: 2018-07-13 Accepted: 2018-07-16 Published online: 2018-08-11
|
Fig. 1. Size of the GM-3564 and GM-3876 glioblastoma subcutaneous tumor xenografts: dynamics of change, control (uninfected human leukocytes) and treatment (leukocytes carrying Coxsackie A7 virus) groups. Δ — leukocytes injected to mice with GM-3564 tumors; ▲ — infected leukocytes injected to mice with GM-3564 tumors ; ○ — leukocytes injected to mice with GM-3876 tumors; ● — infected leukocytes injected to mice with GM-3876 tumors
Table. Coxsackie A7 virus titers found in the blood of the treatment group mice 0–27 days after the injection of virus-infected leukocytes
Note: n. — virus not detected.